Candi-5V is under clinical development by LimmaTech Biologics and currently in Phase II for Vulvovaginal Candidiasis. According to GlobalData, Phase II drugs for Vulvovaginal Candidiasis have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Candi-5V’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Candi5V is under development for the treatment of recurrent vulvovaginal candidiasis. It is a pentavalent conjugate vaccine which is being developed based on bioconjugate vaccine technology.
LimmaTech Biologics overview
LimmaTech Biologics is a clinical-stage biopharmaceutical company focused on the development and manufacturing of novel therapeutic proteins or bioactive molecules. The company conducts clinical trials on shigella bacteria to help prevent diarrheal diseases and Klebsiella studies to prevent klebsiella infections. LimmaTech Biologics’ proprietary bioconjugation platform also enables the research and development of innovative vaccines for a wide range of disease indications. The company specializes in vivo carbohydrate engineering to develop drugs for both the treatment and prevention of life-threatening diseases. It seeks to work in partnership with other pharmaceutical companies for research and development of bioconjugates as vaccines. LimmaTech Biologics is headquartered in Zurich, Switzerland.
For a complete picture of Candi-5V’s drug-specific PTSR and LoA scores, buy the report here.